BriaVax is a gene-modified cell therapy commercialized by BriaCell Therapeutics, with a leading Phase III program in Metastatic Breast Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 2 were completed, 3 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of BriaVax’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for BriaVax is expected to reach an annual total of $128 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

BriaVax Overview

Bria-IMT (BriaVax) is under development for the treatment of advanced metastatic breast cancer, triple-negative breast cancer, HER2+ breast cancer and HER2- breast cancer. The vaccine candidate  is administered intradermally. The vaccine candidate is a HER2/neu-positive allogeneic (non-self) breast cancer cell line (SV-BR-1) transfected with the GM-CSF gene to produce the naturally occurring cytokine GM-CSF.

BriaCell Therapeutics Overview

BriaCell Therapeutics is an immuno-oncology biotechnology company that focuses on cancer immunotherapy. The company offers pipeline products such as Bria-IMT and Bria-OTS. Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients’ HLA types. It has operations in the US and Canada. BriaCell Therapeutics is headquartered in West Vancouver, British Columbia, Canada.

For a complete picture of BriaVax’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.